These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8633399)

  • 1. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population.
    Komatsu K; Wehner N; Prestigiacomo AF; Chen Z; Stamey TA
    Urology; 1996 Mar; 47(3):343-6. PubMed ID: 8633399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.
    Prestigiacomo AF; Stamey TA
    J Urol; 1996 Jun; 155(6):1977-80. PubMed ID: 8618301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraindividual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma.
    Yan Y
    Cancer; 2001 Aug; 92(4):776-80. PubMed ID: 11550147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems.
    Manseck A; Pilarsky C; Froschermaier S; Menschikowski M; Wirth MP
    Urol Int; 1998; 60(1):25-7. PubMed ID: 9519417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer.
    Schambeck CM; Schmeller N; Stieber P; Jansen HM; Pahl H; Schneider W; Fateh-Moghadam A
    Urology; 1995 Aug; 46(2):195-9. PubMed ID: 7542821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The investigation of age-specific PSA reference range as the cut-off values in the mass screening for prostatic cancer].
    Nakanishi H; Nakao M; Nomoto T; Miki T; Nakagawa S; Kitamura K; Watanabe H
    Nihon Hinyokika Gakkai Zasshi; 1999 Nov; 90(11):853-8. PubMed ID: 10598449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of prostate specific antigen for early stage prostate cancer detection.
    Imai K; Ichinose Y; Kubota Y; Yamanaka H; Sato J; Saitoh M; Watanabe H; Ohe H
    Jpn J Clin Oncol; 1994 Jun; 24(3):160-5. PubMed ID: 7516445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
    Kato M; Okada K
    Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
    Oesterling JE; Jacobsen SJ; Klee GG; Pettersson K; Piironen T; Abrahamsson PA; Stenman UH; Dowell B; Lövgren T; Lilja H
    J Urol; 1995 Sep; 154(3):1090-5. PubMed ID: 7543605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraindividual variation in total and percent free prostate-specific antigen levels in prostate cancer suspects.
    Kobayashi M; Kurokawa S; Tokue A
    Urol Int; 2005; 74(3):198-202. PubMed ID: 15812203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
    Aus G; Damber JE; Khatami A; Lilja H; Stranne J; Hugosson J
    Arch Intern Med; 2005 Sep; 165(16):1857-61. PubMed ID: 16157829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.